140 related articles for article (PubMed ID: 31028057)
1. Indinavir Increases Midazolam
Tian DD; Leonowens C; Cox EJ; González-Pérez V; Frederick KS; Scarlett YV; Fisher MB; Paine MF
Drug Metab Dispos; 2019 Jul; 47(7):724-731. PubMed ID: 31028057
[TBL] [Abstract][Full Text] [Related]
2. Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans.
Klieber S; Hugla S; Ngo R; Arabeyre-Fabre C; Meunier V; Sadoun F; Fedeli O; Rival M; Bourrie M; Guillou F; Maurel P; Fabre G
Drug Metab Dispos; 2008 May; 36(5):851-62. PubMed ID: 18256203
[TBL] [Abstract][Full Text] [Related]
3. Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes.
Mao J; Johnson TR; Shen Z; Yamazaki S
Drug Metab Dispos; 2013 Feb; 41(2):343-52. PubMed ID: 23129213
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of 1'- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7.
Seo KA; Bae SK; Choi YK; Choi CS; Liu KH; Shin JG
Drug Metab Dispos; 2010 Nov; 38(11):2007-13. PubMed ID: 20713656
[TBL] [Abstract][Full Text] [Related]
5. An Integrative Approach to Elucidate Mechanisms Underlying the Pharmacokinetic Goldenseal-Midazolam Interaction: Application of In Vitro Assays and Physiologically Based Pharmacokinetic Models to Understand Clinical Observations.
Nguyen JT; Tian DD; Tanna RS; Arian CM; Calamia JC; Rettie AE; Thummel KE; Paine MF
J Pharmacol Exp Ther; 2023 Dec; 387(3):252-264. PubMed ID: 37541764
[TBL] [Abstract][Full Text] [Related]
6. Lack of in vivo correlation between indinavir and saquinavir exposure and cytochrome P450 3A phenotype as assessed with oral midazolam as a phenotype probe.
Robertson SM; Formentini E; Alfaro RM; Falloon J; Penzak SR
Pharmacotherapy; 2006 Aug; 26(8):1051-9. PubMed ID: 16863481
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies.
Prueksaritanont T; Kuo Y; Tang C; Li C; Qiu Y; Lu B; Strong-Basalyga K; Richards K; Carr B; Lin JH
Drug Metab Dispos; 2006 Sep; 34(9):1546-55. PubMed ID: 16782766
[TBL] [Abstract][Full Text] [Related]
8. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.
Fayer JL; Zannikos PN; Stevens JC; Luo Y; Sidhu R; Kirkesseli S
J Clin Pharmacol; 2001 Mar; 41(3):305-16. PubMed ID: 11269571
[TBL] [Abstract][Full Text] [Related]
9. Characterization of 1'-hydroxymidazolam glucuronidation in human liver microsomes.
Zhu B; Bush D; Doss GA; Vincent S; Franklin RB; Xu S
Drug Metab Dispos; 2008 Feb; 36(2):331-8. PubMed ID: 17998299
[TBL] [Abstract][Full Text] [Related]
10. Physiologically Based Pharmacokinetic Modeling to Predict the Impact of Liver Cirrhosis on Glucuronidation via UGT1A4 and UGT2B7/2B4-A Case Study with Midazolam.
Ozbey AC; Keemink J; Wagner B; Pugliano A; Krähenbühl S; Annaert P; Fowler S; Parrott N; Umehara K
Drug Metab Dispos; 2024 Jun; 52(7):614-625. PubMed ID: 38653501
[TBL] [Abstract][Full Text] [Related]
11. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation.
Backman JT; Mäenpää J; Belle DJ; Wrighton SA; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2000 Apr; 67(4):382-90. PubMed ID: 10801247
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory Effect of Oxethazaine on Midazolam Metabolism in Rats.
Namba H; Nishimura Y; Kurata N; Iwase M; Hirai T; Kiuchi Y
Biol Pharm Bull; 2017; 40(9):1361-1365. PubMed ID: 28867721
[TBL] [Abstract][Full Text] [Related]
13. Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A).
Kharasch ED; Bedynek PS; Hoffer C; Walker A; Whittington D
Anesthesiology; 2012 Feb; 116(2):432-47. PubMed ID: 22273859
[TBL] [Abstract][Full Text] [Related]
14. Species differences and substrate specificity of CYP3A heteroactivation by efavirenz.
Kosugi Y; Takahashi J
Xenobiotica; 2015 Apr; 45(4):345-52. PubMed ID: 25387130
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of Action of Panaxytriol on Midazolam 1'-Hydroxylation and 4-Hydroxylation Mediated by CYP3A in Liver Microsomes and Rat Primary Hepatocytes.
He F; Zhang W; Zeng C; Xia C; Xiong Y; Zhang H; Huang S; Liu M
Biol Pharm Bull; 2015; 38(10):1470-7. PubMed ID: 26424012
[TBL] [Abstract][Full Text] [Related]
16. Amenamevir: Studies of Potential CYP3A-Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers.
Adeloye T; Sahgal O; Puri A; Warrington S; Endo T; Dennison J; Johnston A
Clin Pharmacol Drug Dev; 2018 Nov; 7(8):844-859. PubMed ID: 30044899
[TBL] [Abstract][Full Text] [Related]
17. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.
Ito K; Ogihara K; Kanamitsu S; Itoh T
Drug Metab Dispos; 2003 Jul; 31(7):945-54. PubMed ID: 12814973
[TBL] [Abstract][Full Text] [Related]
18. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
[TBL] [Abstract][Full Text] [Related]
19. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation.
Zhang D; Chando TJ; Everett DW; Patten CJ; Dehal SS; Humphreys WG
Drug Metab Dispos; 2005 Nov; 33(11):1729-39. PubMed ID: 16118329
[TBL] [Abstract][Full Text] [Related]
20. Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats.
Kanazu T; Yamaguchi Y; Okamura N; Baba T; Koike M
Xenobiotica; 2004 May; 34(5):403-13. PubMed ID: 15370957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
